ALNY
ALNYLAM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$167.65
−3.65%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$172.70
From 52W high−64.58%
Volume3.50M
Market cap$22.46B
P/E (TTM)8.2x
P/S (TTM)4.5x
Div yield—
Key dataOct 30, 2026
Open
$172.70
From 52W high
−64.58%
Volume
3.50M
Market cap
$22.46B
ValuationView details →
P/E (Fwd)
19.3x
EV/EBITDA
16.1x
P/E (TTM)
8.2x
RSI (14)
23.0
MomentumView details →
1D Return
−3.65%
YTD Return
−57.29%
SummaryUpdated Sep 1, 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a pioneering biopharmaceutical company founded in 2002 and headquartered in Cambridge, Massachusetts. The company went public in 2004 and has established itself as a leader in RNA interference (RNAi) therapeutics, a revolutionary approach to treating diseases by silencing specific genes that cause illness. Alnylam has successfully commercialized multiple RNAi-based medicines and maintains a robust pipeline targeting both rare genetic diseases and more prevalent conditions including cardiovascular, metabolic, and neurological disorders.
Similar companies
Latest newsMore news →
ALNYLAM PHARMACEUTICALS, INC. shares fell 25% amid concerns about slower Amvuttra patient starts and demand, despite a third-quarter earnings beat.2h agoALNYLAM PHARMACEUTICALS, INC. reported quarterly earnings of $16.26 per share, above the Zacks Consensus Estimate of $2.19 per share, compared with $2.90 per share a year earlier.1d agoAlnylam Pharmaceuticals reported third-quarter 2026 revenue of $1,458,086 and GAAP net income of $2,167,335.1d ago